BIOFRONTERA INC

Biofrontera’s 2026 earnings boost its stock to a 52‑week high, spotlighting promising dermatology trials and bright growth prospects.

Discover how Biofrontera Inc. pioneers UV‑induced dermatology treatments, blending R&D innovation with strategic market growth in biopharma.

Biofrontera Inc. has secured a strategic restructuring agreement with its German counterpart, Biofrontera AG, to stabilize its U.S. operations and reduce financial risks, paving the way for long-term stability and growth.